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Abstract 
Purpose: To investigate the effect of sodium phosphate co-transporter (Pit-1) on the regulation of 
monocyte inflammation in diabetic nephropathy uremia (DNU) patients and the underlying principles of 
inflammatory immune response during DNU pathogenesis.  
Methods: The levels of CD14+ CD16+ and Pit-1 on peripheral blood mononuclear cells (PBMC) were 
measured by flow cytometry. Serum C-reactive protein (CRP) and 25(OH)D3 were detected by 
immunoturbidimetry while IL-6 and MCP-1 were assayed with enzyme-linked immunoassay (ELISA). 
The amounts of vitamin D receptors (VDRs) and Pit-1 mRNA in human acute monocytic leukemia cell 
lines (THP-1) were determined by quantitative real-time polymerase chain reaction (qRT-PCR), while 
western blot was utilized for measurement of NF-κB p65 and p-STAT5.  
Results: Compared to the healthy group, DNU patients showed markedly higher CD14+CD16+, Pit-1, 
CRP, IL-6 and MCP-1, while 25(OH) D3 was reduced. Following stimulation with PFA or PTN, 
comparison with DNU group revealed that THP-1 monocytes showed a significant down-regulation of 
Pit-1 (1.34 ± 0.06 for PFA; 1.60 ± 0.25 for PTN; p < 0.05); NF-κB p65 (2.65 ± 0.25 for PFA; 3.88 ± 0.13 
for PTN; p < 0.01), p-STAT5 (2.49 ± 0.10 for PFA; 3.03 ± 0.09 for PTN; p < 0.01) and a significant 
decrease in levels of IL-6 (55.38 ± 3.22 for PFA, 68.68 ± 6.01 for PTN; p < 0.05); MCP-1( 39.67 ± 3.62 
for PFA; 52.62 ± 5.00 for PTN; p < 0.01), except for VDR (0.64 ± 0.15 for PFA, 0.43 ± 0.03 for PTN; p < 
0.05) . 
Conclusion: The level of expression of Pit-1 has a positive correlation with the level of inflammatory 
monocytes, which indicates that Pit-1 can be used as a new biomarker for DNU diagnosis. In addition, 
since Pit-1 is connected to NF-κB and STAT5 signaling pathways which are critical to inflammatory 
immune response, development of drugs that target Pit-1 could be an approach in developing new 
strategies for DNU therapy. 
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Diabetic nephropathy (DN), one of complications 
of diabetes mellitus (DM) plays a pivotal role in 
the development of end-stage renal disease, 
which severely threatens the life of the sufferer 
[1,2]. DN always progresses into uremia, which is 
clinically described as diabetic neuropathy 
uremia (DNU). Therefore, there is the need for 
further studies on DN prevention and treatment. 
Recent evidence has demonstrated that 
inflammatory responses mediated by cytokines 
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participate in DN progression [3,4]. The 
pathological mechanisms of DN development are 
currently believed to be associated with chronic 
infection, genetic mutations, up-regulation of 
macrophage migration inhibitors and pro-
inflammatory monocytes [5]. However, the 
mechanism by which the presence inflammatory 
monocytes in DNU is triggered remains largely 
unclear.    
 
Pit-1, type I of sodium-dependent phosphate 
transporter, NaPi-III, which belongs to the group 
of housekeeping proteins, maintains cell 
metabolism, signal transduction and nucleic acid 
and phospholipid synthesis by phosphorus 
uptake [6]. A large number of animal and cell 
experiments have revealed that Pit-1 is involved 
in vascular calcification of DNU patients [7]. 
However, there is paucity of information on 
whether Pit-1 participates in the stimulation of 
inflammatory monocytes in DNU patients or not, 
and how it does it.  
 
This study examined the effects of Pit-1 on 
inflammatory response of monocytes in DNU 
patients. Its effects on the activities of NF-κB p65 
and pSTAT5 were investigated in the hope that 
the findings will lead to an understanding of the 
role of NF-κB and STAT5 in the progression of 






All those who volunteered to be subjects in this 
study are Chinese Han but not biologically 
related. The healthy group included 10 males 
and 10 females with no history of DM, kidney 
disease, coronary heart disease, hypertension 
and other metabolic disorders, while the DNU 
group without dialysis consisted of 20 females 
and 20 males with urinary albumin excretion > 
300 mg / 24 h [5].  
 
Diagnosis of DNU followed WHO Diagnostic 
Criteria and Classification of Diabetes Mellitus 
1998 [8] and Kidney Disease Outcomes Quality 
Initiative 2012 [9]. The experimental protocol was 
approved by the Ethics Review Board of 
Southwest Hospital, Third Military Medical 
University (ref no. 2013-23) and followed the 




After an 8 h fasting period, blood samples were 
taken from each subject with hypodermic syringe 
and put in appropriately labeled heparinized 
tubes and the plasma samples obtained used for 
biochemical tests. PBMCs, isolated by density 
gradient centrifugation, were washed in non-
serum 1640 culture medium (GIBCO, USA), re-
suspended in RPMI-1640 (GIBCO, USA) 
containing 10 %(v/v) heat-inactivated FCS, 50 
U/mL penicillin as well as 50 mg/mL 
streptomycin. Thereafter, the monocytes were 
cultured in a 96-well plate at a cell density of 
1×106 per well and maintained at 37.0 °C/5 % 
CO2. After collection of supernatants and THP-1 
monocytes, peripheral plasma samples were 
treated with phosphonoformic acid (PFA) or 
parthenolide (PTN) at 1 μg/mL for 24 h. THP-1 
monocytes used in this study were obtained as a 
gift from the Cell Bank of Chinese Academy of 
Sciences. THP-1 monocytes are excellent for 
use in place of mononuclear macrophages for 
the study of the function and status of the latter in 
vitro.  
 
Flow cytometry analysis of monocytes and 
Pit-1  
 
Peripheral blood was pretreated with EDTA and 
then transferred to flow cytometry tubes (150 
μL), followed by the addition of 10 microlitres 
each of CD14-PE, CD16-FITC and Pit-1-FITC 
(AbD Serotec, UK) into appropriately identified 
tubes. At the same time, corresponding tubes 
with identical contents but without fluorescent 
antibody were set up as blank controls. Flow 
cytometry samples were incubated at room 
temperature for 30 min without light, 
supplemented with 1 mL erythrocyte lysis buffer 
and mixed well for 5 min. Cells, harvested in 1 
mL PBS containing 1 % BSA were centrifuged at 
1600 rpm for 10 min and the supernatants 
discarded. The packed cells were rinsed twice 
before fixing them in paraformaldehyde for 10 
min. Mean fluorescent intensities (MFI) of 
CD14+CD16+ and Pit-1 were measured with a 
FACS-Calibur flow cytometer following the 
manufacturers’ instructions (Becton Dickinson, 
USA). 
 
Immunoturbidimetry measurement of 
25(OH)D3 and CRP  
 
Serum 25(OH)D3 and CRP were measured by 
latex particle-enhanced immunoturbidimetry 
(Shanghai Biotechnology, China), according to 
the manufacturers’ protocol.  
 
Determination MCP-1 and IL-6 by ELISA 
 
After appropriate treatments, serum MCP-1 and 
IL-6 were measured by ELISA kit (Takara, 
Japan). Each experiment was carried out in 
triplicate. 
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qRT-PCR for VDR and Pit-1 
 
After 24 h treatment with PFA or PTN, cells were 
collected for RNA extraction using SV Total RNA 
Isolation System (Promega, USA) while TURBO 
DNA-freeTM Kit (Ambion, USA) was used to 
remove DNA contamination. The products of 
reverse transcription were obtained using SYBR® 
PrimeScriptTM RT reagent Kit (Takara, Kusatsu, 
Japan) according to the recommendation of the 
manufacturer. The reverse transcription process 
was performed in a 384-wall plate for real-time 
quantitative PCR using the LightCycler® 480 
system (Roche, Switzerland). Each PCR event 
was repeated at least 3 times.  
 
Western blot analysis p-STAT5 and NF-κB 
p65  
 
Cells were harvested and lysed after PFA or PTN 
treatment for 24 h, and the lysate was 
centrifuged at 12,000 rpm at 4 oC for 10 min. 
Proteins in cytoplasm and nuclei, prepared for 
western blot analysis, were isolated by Extraction 
Kit according to manufacturer’s instructions 
(Thermo Fisher Scientific, USA). Protein 
concentration in supernatant was measured with 
BCA assay kit (Thermo Fisher Scientific, USA). 
Sample was mixed with 6  loading buffer and 
denatured at 100 °C for 5 min. After separation 
by 12 % SDS-PAGE, 30 μg of each sample was 
transferred to PVDF membranes, and then 
blocked by 5 % free-fat milk in TBST at RT for 1 
h. Next, the membranes were incubated with 
specific primary antibodies (Santa Cruz 
Biotechnology, USA) against NF-κB p65 (1: 
3,000), p-STAT5 (1: 2,000), or GAPDH (1: 5,000) 
at 4 ˚C overnight. HRP-labeled secondary goat 
anti-rabbit antibody (1: 3,000) was used at RT for 
2 h. Following three washes in TBST, the 
membranes were treated with ECL (Thermo 
Fisher Scientific, USA) and exposed to x-ray 
films. Image J1.41p software (NIH, USA) was 




Statistical analysis was carried out with SPSS 
13.0. All results are presented as mean ± SD. 
Data for multiple comparisons was analyzed by 
one-way ANOVA, followed by Dunnett’s test. P < 




Analysis on MFI of CD14+CD16+ and Pit-1 in 
monocytes 
 
To determine whether the expression of Pit-1 is 
relevant to local inflammation in DNU patients, 
CD14+CD16+ and Pit-1 levels in monocytes from 
normal control and DNU group were evaluated. 
As shown in Figure 1, CD14+CD16+ MFI was 
significantly higher in DNU group (p < 0.01) and 
Pit-1 MFI in monocytes from DNU patients was 
higher when compared to healthy control (p < 
0.05). 
 
Serum CRP, 25(OH)D3, MCP-1 and IL-6 
 
Table 1 shows that CRP was significantly higher 
in the sera of DNU patients than in those of the 
healthy subjects (healthy subjects 1.49 ± 0.35 
mg/ml, DNU group 5.31±1.34 (mg/ml); p < 0.01) 
while 25(OH)D3 in DNU patients was lower 
compared to normal control (healthy subjects 
42.12 ± 8.18 ng/ml, DNU group 23.17 ± 6.19 
ng/ml; p < 0.05). The results also revealed that 
IL-6 (healthy subjects 11.67 ± 2.95 pg/m, DNU 
group 81.00 ± 15.30 pg/m; p < 0.01) and MCP-1 
(healthy subjects 27.35 ± 4.54 pg/m, DNU group 
56.02±5.93 pg/m; p < 0.01) from DNU group 
were significantly higher than that in healthy 
subjects. There was positive correlation between 
CRP concentration and those of MCP-1 and IL-6. 
 
As shown in Figure 2, expression of Pit-1 was 
positively correlated with CRP concentration (r = 
0.695, p < 0.01, Figure 2A), IL-6 (r = 0.817, p < 
0.01, Figure 2C) and MCP-1 (r = 0.824, p < 0.01, 
Figure 2D), but negatively correlated with 25(OH) 
D3 (r = -0.794, p < 0.01, Figure. 2B). 
 
PFA and PTN inhibit Pit-1 expression 
 
In order to find out whether PFA and PTN could 
inhibit Pit-1, real-time quantitative PCR was used 
to examine Pit-1 in THP-1 monocytes incubated 
with serum from healthy subjects, DNU group, 
PFA-treated DNU group and PTN-treated DNU 
group. As shown in Figure 3A, when compared 
with healthy control, the expression level of Pit-1 
was slightly higher in PFA treated group, 
markedly increased in PTN treated group, but 
significantly up-regulated in DNU group. It has 
been reported that lack of VDR is associated with 
the occurrence of DN and its complications. 
Therefore, changes in VDR levels were 
investigated. The results show that the 
expression level of VDR was exactly opposite to 
that of Pit-1 (Figure 3B). 
 
Suppression of STAT5 and NF-κB activities 
by PFA and PTN  
 
Two leading signaling pathways NF-κB and 
STAT5, are closely involved in inflammatory 
regulation [11]. In order to elucidate the 
mechanism of pro-inflammation regulation effect 
of Pit-1,  
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Figure 1: MFI of CD14+CD16+ and Pit-1 in monocytes (A, B, C, G) Healthy subjects; (D, E, F, H) DN 
uremic patients; flow cytometry analysis MFIs of (AD) A FSC/SSC dot plot displaying monocytes 
identification; (BE) Green lines refer to control antibody staining; (CF) Curve of CD16 expression in 
CD14+; (GH) Curve of Pit-1 expression in CD14+; (I) Statistical of CD16+ and Pit-1expression in 
CD14+ monocytes from 2 groups. CD14+CD16+MFI=C/B or F/E; Pit-1 MFI=G/B or H/E; *p < 0.05, **p 
< 0.01 vs. healthy subjects 
 










Healthy subjects 42.12 ± 8.18 11.67 ± 2.95 27.35 ± 4.54 1.49 ± 0.35 
DN uremia group *23.17±6.19 **81.00 ± 15.30 **56.02±5.93 **5.31 ± 1.34 
*P < 0.05, **p < 0.01 vs. healthy subjects 
 
Western blot was utilized to detect the 
phosphorylation level of NF-κB p65 as well as 
pSTAT5. The results are shown in Figure 4. 
Compared to healthy subjects, NF-κB p65 and p-
STAT5 were markedly higher in DNU, PFA 
treated group and PTN treated group (p < 0.01). 
The phosphorylation levels of pSTAT5 and NF-
κB p65 in DNU patients were increased when 
compared with healthy subjects (p < 0.01). When 
compared with DNU group, the phosphorylation 
levels of pSTAT5 and NF-κB p65 were 
significantly lower in PFA treated and PTN 
treated (p < 0.01). 
 
Attenuation of inflammatory cytokines 
expressions in THP-1 via PFA and PTN 
 
IL-6 and MCP-1 are recognized as important 
cytokines of the inflammatory state that is 
considered to be associated with DN. To confirm 
whether inhibition of Pit-1 could alleviate 
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Figure 2: Spearman correlation of Pit-1 expression and concentration of CRP (A), 25(OH)D3 (B), IL-6 
(C), MCP-1 (D) in DNU group 
 
 
Figure 3: Expression level of Pit-1 (A) and VDR (B) measured by qRT-PCR in THP-1 monocytes 
treated with serum from different groups; *p < 0.05, **p < 0.01 vs. healthy subjects; #P < 0.05, ## P< 
0.01 vs. DNU group; *p < 0.05 vs. DNU group + PFA 
 
inflammation, MCP-1 and IL-6 were measured by 
ELISA in THP-1 after PFA and PTN treatments. 
 
Figure 5A shows that IL-6 in THP-1 monocytes 
was higher in patients of DNU group (89.96 ± 9.8 
pg/mL, p < 0.01), PFA treated group (55.38 ± 
3.22 pg/mL, p < 0.01) and PTN treated group 
(68.68±6.01 pg/mL, p < 0.01), when compared to 
healthy control (14.15 ± 2.72 pg/mL). On the 
other hand, MCP-1 levels in Figure 5B were 
comparable to that of IL-6 (healthy subjects 
24.49 ± 2.43 pg/mL; PFA-treated group 39.67 ± 
3.62 pg/mL, p < 0.01; PTN-treated group 52.62 ± 
5.00 pg/mL, p < 0.01; DNU group, 63.67 ± 5.86 
pg/mL, p < 0.01), indicating that PFA and PTN 
effectively decreased the level of inflammatory 
cytokines, when compared with the levels in 
DNU group. Interestingly, PFA treatment 
effectively decreased IL-6 when compared with 
PTN group, suggesting that the effect of PFA 
was much more effective than that of PTN. 
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Figure 4: Phosphorylation level of NF-κB p65 and pSTAT5. (A) NF-κB p65 and p-STAT5 on THP-1 
from four groups, GAPDH was used as internal control; (B) and (C) represent histogram of NF-κB p65 
and p-STAT5, respectively; **p < 0.01 vs. healthy subjects; ## P<0.01 vs. DNU group; **p < 0.01 vs. 
DNU group + PFA 
 
 
Figure 5: Levels of inflammation related factors in THP-1 cells IL-6 (A) and MCP-1 (B) in the 4 
groups; *p < 0.05, **p < 0.01 vs. healthy subjects; ##P < 0.01 vs. DNU group; *p < 0.05, *p < 0.01 vs. 




The aim of this study was to find out if the 
expression of Pit-1 was associated with 
inflammation in DN uremia patients. The 
variation in levels of NF-κB and STAT5 
expression products as observed in this study 
indicates that PFA and PTN inhibited local 
inflammation by blocking Pit-1. It has been 
proposed that inflammation is a biological 
process that contributes to DNU pathogenesis 
[3]. Recent studies have demonstrated that 
monocytes play an essential role in the onset of 
glomerulopathy and pathogenesis of 
tubulointerstitial lesions associated with DN 
[12,13]. The relationship between monocytes and 
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Pit-1 expression from DNU patients has been 
hardly reported. In this study, CD14+CD16+, a 
pro-inflammatory monocyte subpopulation, 
increased and Pit-1 in monocytes exhibited an 
up-regulated expression in DNU patients, which 
strongly indicates that Pit-1 may be involved in 
the aberrant immune activation present in DNU 
patients. 
 
As is already established, CRP, the acute phase 
reactive protein induced by cytokines, is a 
sensitive indicator of the degree of inflammatory. 
IL-6 and MCP-1 are important inflammatory 
cytokines. In addition, it has been reported that 
low levels of 25(OH)D3 and VD receptor (VDR) 
may be involved in the genesis of the 
complications that occur in DM [14]. This study 
demonstrated that Pit-1 expression is in positive 
correlation with MCP-1 concentration suggesting 
that Pit-1 is associated with monocytes 
dysfunction involved in inflammation and 
pathogenesis of DNU. 
 
Some of functions of THP-1 monocytes are 
similar to those of normal human monocytes. 
Thus it is used to simulate human peripheral 
blood monocytes in vitro [15,16]. In this study, 
THP-1 was used to replace PBMCs. PFA, an 
organic analogue of phosphate, is a competitive 
inhibitor of Pit-1. Previous studies have showed 
that PFA can block expression of OPN and 
Cbf1, two ossification markers of VSMC 
induced by high phosphorus, when phosphorus 
uptake is inhibited [17]. PTN, an inhibitor of NF-
κB, could inhibit the systemic inflammation 
process. Earlier studies have confirmed that PTN 
could relieve the clinical and pathologic 
conditions associated with DN in db/db model, as 
well as decrease the inflammatory factors such 
as MCP-1 and IL-6 [18,19]. The findings of this 
study show that the inflammatory factors 
examined were extremely sensitive to PFA and 
PTN, as evidenced by the significant reduction of 
MCP-1 and IL-6 levels in THP-1, as well as the 
severe intracellular inactivation of p-STAT5 and 
NF-κB p65 pathways in DNU patients. These 
results suggests that NF-κB and STAT5 signaling 
are important in the pathogenesis of DNU. 
Expression of Pit-1, NF-κB and STAT, as well as 
sensitive reaction by inflammatory cytokines in 
monocytes are useful for the treatment and 
prevention of DNU. It is reported that NF-κB, 
defined as a hinge involved in regulating genes 
expression, could induce increases in the 
production of inflammatory cytokines. In the 
present study, PFA and PTN also caused 
decreases in MCP-1 and IL-6 levels, which is an 
indication that PFA and PTN suppressed 
activities of NF-κB and STAT5 via the inhibition 
of Pit-1. 
Pit-1 was previously reported to be required for 
Pi-induced osteogenic differentiation and 
calcification of VSMCs [20]. Furthermore, Pit-1 
mRNA was shown to be up-regulated in uremic 
rat aorta with resultant severe 
hyperphosphatemia [21]. In this study, it was 
found that inflammatory cytokine expressions 
and phosphorylation of NF-κB p65 and pSTAT 
decreased significantly with attendant inhibition 
of Pit-1. This shows that Pit-1was involved the 
activation of NF-κB and STAT pathways. Thus 
Pit-1 participates in monocyte inflammation in 
DNU patients. This fact, combined with the 
finding that PFA and PTN treatment inhibited the 
increase in Pit-1, is suggestive of a possible 
interaction between Pit-1 and the NF-κB and 
STAT5 pathways in the course of inflammation. 
The decreases in IL-6 and MCP-1 associated 
with PFA and PTN proved that the protective 
effect of PFA and PTN on inflammation 
contributes to the suppression of pSTAT5 and 
NF-κB p65 production. Thus, Pit-1 can be 
employed as a new target for treatment of DNU-
induced inflammation. Therefore, a thorough 
understanding of the interaction between Pit-1 
and the NF-κB and STAT5 pathways may 
provide a novel approach to the management of 




The findings of this study suggest that 
suppression of Pit-1 by PFA and PTN treatment 
attenuated the inflammation of monocytes in 
uremic DN patients by regulating the 
phosphorylation of NF-κB p65 and pSTAT5. 
These findings may provide new insight into how 
other therapeutic strategies can be developed for 
the prevention and/or management of 
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